文献速递中医内科中药与中成药合理使用

中药治疗2型糖尿病合并非酒精性脂肪肝的系统评价与Meta分析

Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
PubMed 文献 · Front Pharmacol · 2022-06-27

该系统评价纳入18项随机对照试验共1463例患者,评估中药联合西药对比单用西药治疗2型糖尿病合并非酒精性脂肪肝的疗效与安全性。结果显示联合治疗在改善血脂、肝功能、胰岛素抵抗、血糖、体重及总有效率方面更优,但证据质量较差需谨慎解读。

要点

  • 中药联合西药可改善血脂(TG、TC、LDL-C、HDL-C)及肝功能(ALT、AST)。
  • 联合治疗还可降低胰岛素抵抗、空腹及餐后血糖、体重指数,提高总有效率。
  • 纳入研究报道质量较差,证据不确定性高,结论需谨慎解读。

核心结论

  • 中药联合西药治疗2型糖尿病合并非酒精性脂肪肝在改善脂糖代谢、肝功能、胰岛素抵抗、总有效率及减重方面可能优于单用西药。
  • 因纳入研究报告质量差且证据不确定,上述发现应谨慎解读。

研究设计与样本

  • 系统评价与Meta分析,检索8个电子数据库(建库至2021年12月),纳入18项随机对照试验共1463例参与者。
  • 研究已在PROSPERO注册(CRD42021271488),使用Review Manager 5.2和Stata v14.0进行分析。

主要发现

  • 中药联合西药 vs 单用西药:TG WMD=-0.35(95%CI [-0.51, -0.19],p<0.0001)。
  • TC WMD=-0.58(95%CI [-0.80, -0.36],p<0.00001);LDL-C WMD=-0.37(95%CI [-0.47, -0.26],p<0.00001);HDL-C WMD=0.20(95%CI [0.10, 0.29],p<0.0001)。
  • ALT WMD=-4.99(95%CI [-6.64, -3.33],p<0.00001);AST WMD=-4.76(95%CI [-6.35, -3.16],p<0.00001)。
  • HOMA-IR WMD=-1.01(95%CI [-1.22, -0.79],p<0.00001);空腹血糖 WMD=-0.87(95%CI [-1.13, -0.61],p<0.00001);餐后2小时血糖 WMD=-1.45(95%CI [-2.00, -0.91],p<0.00001)。
  • BMI WMD=-0.73(95%CI [-1.35, -0.12],p=0.02);总有效率 RR=1.37(95%CI [1.29, 1.46],p<0.00001)。

临床怎么用

  • 对2型糖尿病合并非酒精性脂肪肝患者,可考虑在规范西药治疗基础上联合中药以改善血脂、肝功能及胰岛素抵抗。
  • 联合治疗可能有助于降低体重和血糖,但需结合患者个体情况并监测安全性。
  • 因证据质量有限,临床决策应谨慎,并优先参考高质量指南与个体化评估。

局限性

  • 纳入研究的报告质量较差,证据不确定性高,可能影响结论可靠性。
  • 原文未报告具体的偏倚风险评估细节及异质性来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives: To evaluate the efficacy and safety of Chinese herbal medicine (CHM) for type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD) with current evidence. Methods: This study was registered in PROSPERO as CRD42021271488. A literature search was conducted in eight electronic databases from inception to December 2021. The primary outcomes were lipid indices and liver functions, including triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine transaminase (ALT), and aspartate transaminase (AST). Review Manager 5.2 and Stata v14.0 were applied for analysis. Results: The research enrolled 18 RCTs with 1,463 participants. Results showed CHM combined with western medicine (WM) was more effective than WM alone in TG (weighted mean differences (WMD) = -0.35.95% confidence interval (CI) [-0.51, -0.19], p < 0.0001), TC (WMD = -0.58.95%CI [-0.80, -0.36], p < 0.00001), LDL-C (WMD = -0.37, 95%CI [-0.47, -0.26], p < 0.00001), HDL-C (WMD = 0.20, 95%CI [0.10, 0.29], p < 0.0001), ALT (WMD = -4.99, 95%CI [-6.64, -3.33], p < 0.00001), AST (WMD = -4.76, 95%CI [-6.35, -3.16], p < 0.00001), homeostatic model assessment of insulin resistance (WMD = -1.01, 95%CI [-1.22, -0.79], p < 0.00001), fasting blood glucose (WMD = -0.87, 95%CI [-1.13, -0.61], p < 0.00001), 2-h postprandial glucose (WMD = -1.45.95%CI [-2.00, -0.91], p < 0.00001), body mass index (WMD = -0.73.95%CI [-1.35, -0.12], p = 0.02), and overall effective rate (risk ratio (RR) = 1.37.95%CI [1.29, 1.46], p < 0.00001). Conclusion: The CHM in combination with WM seems to be more beneficial in T2DM with NAFLD patients in improving lipid and glucose metabolism, liver function, and insulin resistance as well as improving overall efficiency and reducing body weight. Given the poor quality of reports from these studies and uncertain evidence, these findings should be interpreted cautiously. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021271488, identifier CRD42021271488.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Peng S, Liu L, Xie Z, et al. Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Pharmacol. 2022. PMID: 35833030. doi:10.3389/fphar.2022.863839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。